Repository of Research and Investigative Information

Repository of Research and Investigative Information

دانشگاه علوم پزشکی و خدمات بهداشتی درمانی زنجان

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study

(2008) Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study. Human Psychopharmacology. pp. 79-86.

Full text not available from this repository. (Request a copy)

Official URL: http://apps.webofknowledge.com/full_record.do?prod...

Abstract

It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI-B), at low doses would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far. This study was designed to investigate the effect of selegiline added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in an 8 week, double blind and randomized clinical trial. Methods Eligible participants in this study were 40 patients with chronic schizophrenia. All patients were inpatients and were in the active phase of the illness, and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion, 20 to risperidone 6 mg/day plus selegiline 10 mg/day (5 mg bid) and 20 to risperidone 6 mg/day plus placebo. The principal measure of the outcome was Positive and Negative Syndrome Scale (PANSS). Results Although both protocols significantly decreased the score of the positive, negative, and general psychopathological symptoms over the trial period, the combination of risperidone and selegiline showed a significant superiority over risperidone alone in decreasing negative symptoms and PANSS total scores. Conclusion The present study indicates selegiline as a potential adjunctive treatment strategy for the negative symptoms of schizophrenia. Nevertheless, results of larger controlled trials are needed before recommendation for a broad clinical application can be made. Copyright (C) 2007 John Wiley & Sons, Ltd.

Item Type: Article
Keywords: Author Keywords:monoamine oxidase inhibitor-B; selegiline; schizophrenia KeyWords Plus:PHARMACOLOGICAL-TREATMENT; ANTIPSYCHOTIC MEDICATION; AUGMENTATION; OUTPATIENTS; SCALE
Page Range: pp. 79-86
Journal or Publication Title: Human Psychopharmacology
Abstract and Indexing: ISI, Pubmed, Scopus
Quartile : Q2
Volume: 23
Number: 2
Publisher: scopus
Depositing User: خانم مریم زرقانی
URI: http://repository.zums.ac.ir/id/eprint/952

Actions (login required)

View Item View Item